Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized sellers, manufacturers and distributors of copycat versions of the medicine.
In lawsuits filed Wednesday in the U.S. District Court for the Northern District of California, Lilly accused the sites — Mochi Health, Fella Health, Willow Health and Henry Meds — of deceiving consumers about 'untested, unapproved drugs.'
Lilly also alleged some of the sites are selling versions of the drugs that haven't been studied, such as oral tablets and drops.
For instance, Henry Meds sells what it claims is an oral version of tirzepatide, the active ingredient in Lilly's drugs.
But Lilly in the lawsuit argued the oral version 'is an untested knockoff that exposes patients to safety risks' because no clinical study has found tirzepatide taken orally is safe and effective.
'Lilly's tirzepatide medicines are only tested and approved for under-the-skin injections— not for administration in any oral form,' the company wrote.
In a new approach, Lilly also accused Mochi and Fella of engaging in the corporate practice of medicine. The lawsuit claims neither company is owned by a physician, and that the telehealth companies exert influence and control over their supposedly 'independent' affiliated medical groups.
Fella Health, which also operates a brand called Delilah for women, is affiliated with Fella Medical Group, while Mochi Health is affiliated with Mochi Medical, according to the lawsuits.
In its filing, Lilly claimed Mochi CEO Myra Ahmad is not a licensed physician
'Mochi Health and its unlicensed owners exercise undue influence and control over, among other things, the prescribing decisions of physicians at Mochi Medical—and, as a result, engage in, and aid and abet, the unlawful corporate practice of medicine,' Lilly said in its complaint against Mochi.
In its complaint against Fella Health, Lilly said the company made 'sweeping corporate decisions that dictate patient care, such as when Fella changed patients en masse from one tirzepatide formulation to another with additives.'
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, so long as the FDA considered them in shortage.
Compounded drugs are sold at vastly lower prices than the branded versions, but drug companies and some obesity specialists have expressed concerns that compounded products aren't safe because they are not FDA-approved.
Lilly's diabetes drug Mounjaro went into short supply in late 2022, though the FDA has since declared the shortage over, meaning mass compounding was supposed to stop.
But some compounders have argued they can continue marketing the drugs if they are administered in nonstandard doses, and if the compounded drugs are prescribed by a health care provider to meet a clinical need.
Lilly argued that Fella and Mochi Fella 'unilaterally' changed the prescriptions for compounded tirzepatide. Fella allegedly required patients to take doses manipulated with additives, while Mochi changed from doses similar to Lilly's to lower doses 'that have never been studied.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar
Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall issued on May 23 affects the 12-ounce aluminum cans of a 12-pack and 24-pack case of Dr Pepper Zero Sugar. 'Product labeled to be zero sugar contains full sugar product,' the FDA wrote about the drink. The recalled product contains the same amount of sugar found in regular Dr Pepper, which is 39 grams per can. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The cans were made by Pepsi Beverages Company in Jacksonville, Florida and distributed to only Florida, Georgia and South Carolina. On June 5, the FDA then classified the product as a class II recall. This level of recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. See the full recall here. Recall alert: These window air conditioners could cause mold exposure Recall alert: Bring these crackers back to the store due to undeclared allergen Recall alert: Throw away these 17 salads, salsas due to salmonella concern Read the original article on MassLive.
Yahoo
3 hours ago
- Yahoo
Parents are dismayed after FDA rejects experimental drug 4-year-old girl relies on
A family thought they had a life-changing drug for their 4-year-old daughter. Then the FDA rejected it. Channel 2's Michael Doudna heard from the girl's parents. For Hope Filchak, her daily routine includes a daily shot to help provide a normal life. However, soon the drug may go away. 'It's scary to think she might not have this in just a few months,' Caroline Filchak, Hope's mother, said. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] Hope was born with a rare mitochondrial disease that impacts fewer than 100 people in the world. The impacts are wide-ranging and a challenge to overcome. 'From early on, it was an uphill battle for Hope,' Caroline Filchak said. 'I think she's got 12 specialists that we see in three different states.' 'It affects her brain, her heart, her eyes and her ears, deafness, blindness, and then two heart defects,' Ben Filchak, Hope's father, said. There are no FDA-approved drugs for Hope's condition. So when heart troubles arose in 2024, the family was forced to turn to an experimental drug, elemipretide, and saw immediate improvement. 'Her energy increased, and her heart function has stabilized completely,' Ben Fiilchak said. However, last month, the FDA declined to give it approval. 'I would say that the FDA is trying to regulate two things, right. They're trying to make sure the products are safe, including drugs, but also that they are efficacious for people,' said Rossana Sanchez Russo, an Emory clinical geneticist. According to the parent company producing the drug, the FDA's rejection was in part because the FDA did not see an improvement in a six-minute walk test. 'We all know in the field that a six-minute walk test is not the be-all end-all outcome measure for mitochondrial diseases,' Amy Goldstein, a leading mitochondrial disease expert, said. She says the drug showed improvement in areas such as quality of life and cardiac health. 'I myself personally saved a baby in my cardiac ICU with Barre syndrome. He went home with no cardiac manifestations after arriving here in severe heart failure and needing a heart transplant,' Goldstein said. 'We were extremely disappointed that based on all of the data, they made the decision not to approve the drug.' Another hurdle rare disease drug testing faces is sample size. By its very nature, only a few people have these diseases, so getting a meaningful sample during clinical trials can be difficult. 'Sometimes we don't have enough burden of proof to be able to formally say that. That doesn't mean that it may not be working for a family or that it might not work for other conditions. It may mean that we just do not have all the data,' Sanchez Russo said. The FDA says the company behind the drug can reapply for approval, but it is unclear if it will be successful and how long the company can stay committed to producing a drug without the FDA giving an OK. Hope's family has a four-month supply of the drug left. However, they do not know how much longer access to the medicine will last. 'Hope is a special little girl, and she means so much to our family,' Caroline Filchak said. TRENDING STORIES: Raids uncover largest fentanyl pill operation in state history in Atlanta, Douglasville Hurricane season starts quietly in the Atlantic They were once best friends, then one killed the other. We take you inside this bizarre murder case [SIGN UP: WSB-TV Daily Headlines Newsletter]
Yahoo
3 hours ago
- Yahoo
Roughly 20,000 Cases of Popular Soda Have Been Recalled
Nearly 20,000 cases of soda were recalled by the U.S. Food & Drug Administration due to misleading labels. On May 23, the U.S. Food & Drug Administration initiated a recall for 19,203 cases of Dr Pepper Zero Sugar. Although they labeled as "zero sugar," the cans in these 12-pack and 24-pack cases actually contained full sugar. A regular 12-ounce can of Dr Pepper contains 39 grams of sugar. That'd be unsafe to drink if you're diabetic. The FDA ruled this a Class II recall, which means the produce could cause "temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." The cases of Dr Pepper that were recalled by the FDA were found in Florida, Georgia and South Carolina. At this time, no other Dr Pepper products were impacted by the FDA's Class II recall. The FDA states that recalled products can often be returned to where they were originally purchased. However, that's not always the case. "A medical device recall does not always mean that you must stop using the product or return it to the company. A recall sometimes means that the medical device needs to be checked, adjusted, or fixed. Contact your health care provider for additional guidance," the FDA's guidelines state. "If you cannot return a product, dispose of the product properly. If it's contaminated, ensure it is in a secure container and place the item in a covered trash can or dumpster so no people or animals can access it. Be sure to follow your local disposal laws." Roughly 20,000 Cases of Popular Soda Have Been Recalled first appeared on Men's Journal on Jun 10, 2025
